미국의 영업 비밀 소송 호황기
This is a boom time for trade secret litigation in the U.S. The underlying conditions driving the boom include the growing mobility of the global workforce, the ease with which electronic data can be...more
Legal regimes are shifting, including in the intellectual property world as businesses increasingly seek the protection of trade secrets rather than patents to secure their confidential information. When the Defend Trade...more
9/24/2024
/ Damages ,
Data Protection ,
Defend Trade Secrets Act (DTSA) ,
Employees ,
Employer Liability Issues ,
Federal Trade Commission (FTC) ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Misappropriation ,
Patents ,
Trade Secrets
Trade secrets and patents offer very different forms of protection, with different pros and cons. A trade secret may last indefinitely, while a patent has a fixed term of 20 years. Independent reinvention is permissible under...more
During the Obama Administration, American foreign policy made a strategic “pivot” to Asia with the goal of establishing a more balanced economic, diplomatic, and security-focused approach and relationship between the U.S. and...more
Why should companies considering trade secret litigation consider their patent portfolios? After all, trade secrets, by definition, are secret. They have value in the marketplace by virtue of not being disclosed. And like the...more
9/23/2020
/ Certiorari ,
Claim Construction ,
Damages ,
Defend Trade Secrets Act (DTSA) ,
Disclosure Requirements ,
Intellectual Property Protection ,
Misappropriation ,
Non-Disclosure Agreement ,
Patents ,
Popular ,
Remand ,
Technology Sector ,
Trade Secrets ,
Trademark Infringement ,
UTSA
As the COVID-19 pandemic spreads throughout the United States and Americans anxiously await the arrival of a vaccine, biotech companies are grappling with the uncertainty of patent protection for COVID related biomedical...more
9/15/2020
/ Biomedical Advanced Research and Development Authority (BARDA) ,
Centers for Disease Control and Prevention (CDC) ,
Collaboration ,
Coronavirus/COVID-19 ,
Department of Health and Human Services (HHS) ,
Eligibility ,
Food and Drug Administration (FDA) ,
Intellectual Property Protection ,
National Institute of Health (NIH) ,
OSTP ,
Patent Act ,
Patents ,
Policy Drafting ,
Section 101 ,
Trade Secrets ,
Transparency
As the world grapples with its response to COVID-19, the availability and nature of intellectual property protection afforded for diagnostic tests, treatments, vaccines, and accompanying data is likely to have a significant...more